Ardena Bioanalysis
Ardena Bioanalysis is recorded as a service provider in 30 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 30 trials · Latest update first
A multicenter, multinational, pharmacokinetic, safety, and efficacy study with IV NEPA (fosnetupitant/palonosetron) for the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients undergoing highly emetogenic chemotherapy (HEC). A 2-part study with Phase 2, open-label, randomized, single-dose IV NEPA vs fosaprepitant/ondansetron in single-day HEC and repeated-dose IV NEPA in multi-day HEC (Part I, single cycle) and with Phase 3, double-blind, randomized, repeated-dose IV NEPA vs aprepitant/ondansetron in multi-day HEC (Part II, repeated cycles).
Sponsor Helsinn Healthcare S.A.
- Start (EU)
- Latest update
- Estimated end
A Phase 2a double blind, randomized, parallel arm, placebo-controlled trial to investigate the effects of two dose levels of CIT-013 on disease activity in patients with Hidradenitis Suppurativa (HS)
Sponsor Citryll B.V.
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered GLPG3667 in adult subjects with active systemic lupus erythematosus.
Sponsor Galapagos
- Start (EU)
- Latest update
- Estimated end
Operational learnings available1 trial-level finding · Read insights
- Of 84 activated sites, 68 screened at least one subject and 57 randomized subjects across Argentina, Bulgaria, Chile, Germany, Spain, France, Georgia, Hungary, Peru, Poland, Puerto Rico, and the US.
These findings describe the trial, not the service provider’s performance or responsibility.
A 2-part phase 1/2 open-label trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ODM-212 in combination with anti-cancer therapy in participants with advanced solid tumours
Sponsor Orion Corporation
- Start (EU)
- Latest update
- Estimated end
MK-5684-004: A Phase 3, Randomized, Open-label Study of Opevesostat Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (OMAHA-004)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
A Two-Part Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of MK-7480 in Healthy Participants
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available1 trial-level finding · Read insights
- Amendment 03 added Panel D to evaluate safety, tolerability, and pharmacokinetics at higher MK-7480 doses in light of emerging pharmacokinetic data.
These findings describe the trial, not the service provider’s performance or responsibility.
A Cancer Research UK Phase II trial of CY-101 given via intratumoural administration in locally advanced or metastatic adrenocortical carcinoma (CLARITY)
Sponsor Cancer Research UK
- Start (EU)
- Latest update
- Estimated end
A Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of MK-3508 in Healthy Participants
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available4 trial-level findings · Read insights
- Amendments added two panels to explore higher MK-3508 doses.
- Planned doses were revised downward based on emerging pharmacokinetic data.
- An amendment added inclusion-criteria requirements and an additional stopping criterion.
- An amendment clarified concomitant-medication restrictions and study procedures and added safety monitoring.
These findings describe the trial, not the service provider’s performance or responsibility.
A Multiple-Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-4318 in Healthy Participants
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available1 trial-level finding · Read insights
- Adult participants were recruited at one study site in Belgium, with 32 participants enrolled.
These findings describe the trial, not the service provider’s performance or responsibility.
Efficacy and tolerability of tasipimidine after 3 repeated bed-time doses in patients with insomnia disorder with a 4-week extension part
Sponsor Orion Corporation
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- Protocol Amendment 2 extended the trial period and increased the number of sites.
- Protocol Amendment 4 extended Part 2 treatment from 3 days in a sleep laboratory to a 4-week period in the sleep laboratory and at home.
- Part 3 was not started because the interim analysis of Parts 1 and 2 showed no significant primary-endpoint efficacy for any tasipimidine dose versus placebo.
These findings describe the trial, not the service provider’s performance or responsibility.
Phase 1/2 study with an open-label dose escalation phase followed by a randomized, double-blind phase of SLN124 in patients with Polycythemia Vera
Sponsor Silence Therapeutics PLC
- Start (EU)
- Latest update
- Estimated end
A Phase III, randomised, double-blind, placebo-controlled, parallel-group, pivotal trial to assess the efficacy and safety of sonlicromanol in adult subjects with a genetically confirmed mitochondrial DNA tRNALeu(UUR) m.3243A>G variant.
Sponsor Khondrion B.V.
- Start (EU)
- Latest update
- Estimated end
A single-center, randomized, double-blind, placebo-controlled, parallel-group, proof-of-concept trial to assess the efficacy and safety of ACT-1004-1239 in adults with progressive multiple sclerosis
Sponsor Idorsia Pharmaceuticals Ltd.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 1/2, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Intravenous Doses of BMN 351 in Participants with Duchenne Muscular Dystrophy
Sponsor Biomarin Pharmaceutical Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled, 3-Part Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-demand Treatment of Angioedema Attacks in Adults with Acquired Angioedema due to C1 Inhibitor Deficiency
Sponsor Pharvaris Netherlands B.V.
- Start (EU)
- Latest update
- Estimated end
A Long-term, Open-label Study to Evaluate the Safety and Efficacy of Orally Administered Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema
Sponsor Pharvaris Netherlands B.V.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant Extended-release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema
Sponsor Pharvaris Netherlands B.V.
- Start (EU)
- Latest update
- Estimated end
A Phase II, Double-blind, Placebo-controlled, Randomized, Dose-ranging, Parallel Group Study to Evaluate the Safety and Efficacy of PHA-022121 Administered Orally for Prophylaxis Against Angioedema Attacks in Patients with Hereditary Angioedema due to C1-Inhibitor Deficiency (Type I or Type II)
Sponsor Pharvaris Netherlands B.V.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Attacks in Adolescents and Adults with Hereditary Angioedema.
Sponsor Pharvaris Netherlands B.V.
- Start (EU)
- Latest update
- Estimated end
A phase 1/2, first-in-human study on ODM-212 in subjects with selected advanced solid tumours
Sponsor Orion Corporation
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Ardena Bioanalysis?
The 2026-10-09 snapshot links Ardena Bioanalysis to 30 distinct CTIS trials. Recorded services include Laboratory services, analyze PK samples and CSF, Biological samples testing and storage, Pharmacokinetic analysis, among 7 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Ardena Bioanalysis?
The most frequently recorded therapeutic areas are Neurology, Solid Tumor Oncology, Immunology, Genetic and Congenital Disorders. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Ardena Bioanalysis conducted?
The linked trials record locations in 24 countries, including Spain, Germany, Poland, France, Italy. These are trial locations, not confirmed office locations or countries where Ardena Bioanalysis delivered services.
What can this page tell me about Ardena Bioanalysis's trial experience?
Browse 30 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 5 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Ardena Bioanalysis. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Ardena Bioanalysis B.V.